These symptoms disrupt treatment and day-to-day living ... and negative symptoms and improve cognitive issues in some people ...

The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...

US regulators have approved a new treatment for schizophrenia, the first of its kind targeting the mental condition in ...

One of the drugs Royalty Pharma owns a stake in is Cobenfy, the new schizophrenia treatment from Bristol Myers Squibb. At its ...

A year of recovery After a challenging period, 2024 has seen a more positive backdrop emerge for the biotechnology sector. In ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.

ASX could hit record high despite mixed bag on Wall Street. US stocks expected to outperform bonds as Fed cuts rates.

Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...